Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04623710 · ClinicalTrials.gov registry record · Phase 1
Study of ALXN2050 in Participants With Renal Impairment
A Phase 1 study, sponsored by Alexion Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT04623710 is a Phase 1 study that has completed, run by Alexion Pharmaceuticals. The registered enrollment target is 40 participants.
The verdict
NCT04623710, a Phase 1 study, has completed, sponsored by Alexion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
This study will investigate the impact of impaired renal function on the plasma pharmacokinetics of ALXN2050 in order to provide dosing recommendations for future indications in individuals with impaired renal function.
Interventions
- DRUG ALXN2050
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2021-07-08 |
| Est. Completion | 2022-03-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04623710
The ClinicalTrials.gov registry entry for NCT04623710 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ALXN2050 is the first listed.
NCT04623710 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04623710 about?
NCT04623710 is a clinical study titled "Study of ALXN2050 in Participants With Renal Impairment". This study will investigate the impact of impaired renal function on the plasma pharmacokinetics of ALXN2050 in order to provide dosing recommendations for future indications in individuals with impaired renal function.
What is the current status of trial NCT04623710?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2021-07-08. Estimated completion is 2022-03-21.
What interventions are being tested in trial NCT04623710?
The interventions under investigation include: ALXN2050 (DRUG).
Who is sponsoring clinical trial NCT04623710?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.